

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: Andrew R. Marks

Confirmation No.: 7653

Application No.: 10/809,089

Group Art Unit: 1612

Filing Date: March 25, 2004

Examiner: Benjamin J. Packard

For: NOVEL ANTI-ARRHYTHMIC AND
HEART FAILURE DRUGS THAT TARGET THE
LEAK IN THE RYANODINE RECEPTOR (RyR2)
AND USES THEREOF

Attorney Docket No.: 86005-59600

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Box Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


Sir:

Pursuant to applicants' duty of disclosure under 37 C.F.R. 1.56, enclosed is a Form PTO-1449 listing six (6) references for the Examiner's review and consideration. These references were cited in related applications but none are deemed to material to the patentability of the allowed claims. Copies of these references are enclosed.

It is respectfully requested that these references be made of record in this application by the Examiner's completion and return of the PTO Form 1449. The undersigned hereby certifies under 37 CFR 1.97(e)(1) that each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Pursuant to 37 CFR 126 1.17(p), a fee of \$180 is be due for the filing of this statement. Please charge the required fee to WINSTON & STRAWN LLP Deposit Account No. 50-1814.

Respectfully submitted,



Allan A. Fanucci,

(Reg. No. 30,256)

Date: March 26, 2010

WINSTON & STRAWN LLP
Customer No. 28765
212-294-3311